

Law No. (17) of 2026
Establishing the
Dubai Longevity Authority¹

We, Mohammed bin Rashid Al Maktoum, Ruler of Dubai,

After perusal of:

Federal Law No. (4) of 2015 Concerning Private Healthcare Facilities, its Implementing Bylaw, and their amendments;

Federal Law by Decree No. (4) of 2016 Concerning Medical Liability, its amendments, and its Implementing Bylaw;

Federal Law No. (2) of 2019 Concerning the Use of Information and Communications Technology in Health-related Fields and its Implementing Bylaw;

Federal Law by Decree No. (28) of 2023 Establishing the Emirates Drug Establishment;

Federal Law by Decree No. (38) of 2024 Concerning Medical Products, Pharmaceutical Profession, and Pharmaceutical Establishments;

Law No. (13) of 2011 Regulating the Conduct of Economic Activities in the Emirate of Dubai and its amendments;

Law No. (1) of 2016 Concerning the Financial Regulations of the Government of Dubai, its Implementing Bylaw, and their amendments;

Law No. (6) of 2018 Concerning the Dubai Health Authority and its amendments;

Law No. (5) of 2021 Concerning the Dubai International Financial Centre;

Law No. (8) of 2021 Concerning Human Resources Management of Executive Directors/ Chief Executive Officers in the Government of Dubai and its amendments;

Law No. (13) of 2021 Establishing the Dubai Academic Health Corporation,

Law No. (26) of 2023 Concerning the Executive Council of the Emirate of Dubai;

©2026 The Supreme Legislation Committee in the Emirate of Dubai

¹*Every effort has been made to produce an accurate and complete English version of this legislation. However, for the purpose of its interpretation and application, reference must be made to the original Arabic text. In case of conflict, the Arabic text will prevail.*

Law No. (17) of 2026 Establishing the Dubai Longevity Authority

Law No. (19) of 2024 Regulating Law Enforcement Capacity in the Emirate of Dubai and its Implementing Bylaw;

Law No. (5) of 2025 Concerning Public Health in the Emirate of Dubai;

Decree No. (22) of 2009 Concerning Special Development Zones in the Emirate of Dubai;

Decree No. (1) of 2023 Concerning Governance of the Councils/ Boards and Committees Affiliated to the Government of Dubai;

Decree No. (13) of 2024 Establishing the Unified Digital Window for Establishing Companies in the Emirate of Dubai;

Executive Council Resolution No. (49) of 2024 Regulating the Practice of Health Professions and Health Activities in the Emirate of Dubai; and

The legislation establishing and regulating free zones in the Emirate of Dubai,

Do hereby issue this Law.

Title of the Law

Article (1)

This Law will be cited as "Law No. (17) of 2026 Establishing the Dubai Longevity Authority".

Definitions

Article (2)

The following words and expressions, wherever mentioned in this Law, have the meanings respectively assigned to them, unless the context implies otherwise:

Emirate:	The Emirate of Dubai.
Ruler:	His Highness the Ruler of Dubai.
Government:	The Government of Dubai.
Executive Council:	The Executive Council of the Emirate of Dubai.
DHA:	The Dubai Health Authority.
DLA:	The Dubai Longevity Authority.

Concerned Entity:	Any local Government Entity legally vested with the authority to oversee and supervise any of the fields or activities related to Longevity in accordance with the legislation applicable to that entity, including the DHA, the DAHC, the DET, and the DM.
President:	The President of the DLA.
Board of Directors:	The board of directors of the DLA.
Executive Director:	The executive director of the DLA.
Longevity:	The process of improving, promoting, and sustaining an individual's healthspan and enhancing his health-related quality of life by: 1. comprehensively addressing the requirements for healthspan-enhancing solutions through therapeutic and preventive interventions that contribute to delaying the emergence of biological signs and markers of ageing, correcting the pathways associated with such signs and markers upon their onset, and activating the body's restorative, regenerative, and protective mechanisms; 2. adopting advanced health and well-being innovations and technological solutions in a manner that promotes holistic health and supports responsible and sustainable lifestyles; 3. developing methods for the accurate measurement and early detection of biological markers of ageing, and implementing proactive intervention programmes to improve such markers in accordance with scientific protocols and using advanced diagnostic tools; 4. undertaking the assessment, treatment, optimisation, and continuous monitoring of health conditions associated with age, lifestyle, and environmental factors affecting individuals, including conditions of a physical, physiological, psychological, and biological nature; and 5. utilising advanced therapeutic technologies, methods, and products in proactive therapeutic and preventive

interventions, and leveraging the outputs of scientific research and development to study and analyse ageing processes and support and enhance the body's functional capacities.

Activity:	Any of the following activities carried out in the Emirate and relating to any of the fields of Longevity: 1. developing, evaluating, and disseminating advanced medical treatments or applied therapies; 2. conducting research and development activities and laboratory and clinical trials, in accordance with the requirements and controls adopted by the DLA in coordination with the Concerned Entities; 3. providing therapeutic, preventive, and medical services and interventions; 4. promoting, marketing, selling, or distributing products related to Longevity, including Advanced Therapeutic Products; or 5. conducting any other activity determined pursuant to a resolution of the Board of Directors.
Advanced Therapeutic Product:	Any method, technology, or therapeutic product based on biological repair, regeneration, or functional restoration of the body, intended to promote Longevity and enhance an individual's health-related quality of life.
Permit:	A document issued by the DLA authorising an Establishment to conduct the Activity, subject to compliance with the conditions and procedures adopted in this regard.
Establishment:	A Company or sole proprietorship licensed by the competent commercial licensing authority in the Emirate and authorised by the DLA to conduct the Activity.

Establishment of the DLA

Article (3)

Pursuant to this Law, a public corporation named the “Dubai Longevity Authority” is established. The DLA will have legal personality and the legal capacity required to undertake all acts and dispositions that ensure the achievement of its objectives.

Head Office of the DLA

Article (4)

The head office of the DLA will be located in the Emirate. Other branches and offices of the DLA may be established within and outside the Emirate pursuant to a resolution of the President.

Objectives of the DLA

Article (5)

The DLA will have the following objectives:

1. enhance the Emirate’s position as a leading global hub for Longevity and Advanced Therapeutic Products by developing a world-class ecosystem that attracts Companies and talent, and supports research programmes and strategic partnerships in these fields;
2. promote the health and wellbeing of residents of and visitors to the Emirate by enabling approved preventive, regenerative, restorative and science-based Activities related to the physical health of individuals; designing personalised health programmes; providing proactive, safe, and effective therapeutic and preventive interventions; and supporting diverse and sustainable healthy lifestyle options;
3. develop integrated regulatory frameworks in the fields of Longevity that ensure safety, efficacy, ethical integrity, transparency, and the protection of individuals; and establish a safe and responsible environment for the gradual adoption of Advanced Therapeutic Products;
4. contribute to the enhancement of research, development, and technological capabilities in the fields of Longevity by supporting clinical studies and scientific trials; facilitating the structured transition from discovery to clinical practice and the commercialisation of services and products related to Longevity; promoting the responsible adoption of related solutions; and enhancing public knowledge and awareness of such services, products, and solutions;

5. enhance cooperation and strategic partnerships among academic, healthcare, industrial, and technology entities and healthcare providers, with a view to facilitating the exchange of expertise, the transfer of knowledge, and the development of advanced health solutions, thereby contributing to Longevity; and
6. support the economic infrastructure of the Longevity sector by attracting investment, specialised talent, and industrial capabilities; facilitating the transfer of technology and business models related to Longevity activities and services; and developing an advanced market for Advanced Therapeutic Products and other services and products related to the fields of Longevity.

Functions of the DLA Article (6)

For the purpose of achieving its objectives, the DLA will, in coordination with the Concerned Entities, have the duties and powers to:

1. develop the general policy and strategic plans for Longevity in the Emirate, and submit the same to the Board of Directors for approval in preparation for final approval by the President;
2. develop and approve the regulations, rules, bylaws, standards, and protocols governing the conduct of the Activity within the Emirate;
3. develop and operate integrated technological and digital systems, and link them to approved Government platforms to manage procedures for issuing Permits and Approvals and conducting regulatory processes; verify compliance with the legislation, regulations, bylaws, and protocols governing Longevity; issue reports; and facilitate the exchange of data between the DLA and the Concerned Entities;
4. regulate the conduct of the Activity in the Emirate and the provision of programmes and solutions related to Longevity, in accordance with the requirements, procedures, and controls adopted in this regard;
5. authorise, through the Unified Digital Window regulated under the above-mentioned Decree No. (13) of 2024, Establishments to conduct the Activity in the Emirate in accordance with the requirements, procedures, and controls adopted in this regard;
6. issue the necessary approvals for natural persons to conduct the Activity and provide services, products, and solutions related to Longevity, in accordance with the requirements, procedures, and controls adopted in this regard;

7. supervise, monitor, and inspect Establishments conducting the Activity in the Emirate; and ensure their compliance with the provisions of this Law, the resolutions issued in pursuance hereof, other legislation in force in the Emirate, and the terms of the Permit;
8. classify and define the Activities that may be conducted in the Emirate in relation to any of the fields of Longevity and Advanced Therapeutic Products, and develop the regulations and rules governing the conduct of such Activities and the provision of services, products, and solutions related to those fields;
9. regulate research trials, prototype development, and pilot programmes in the field of Longevity; and regulate and supervise the procedures for the application of therapeutic tools and technologies that are the subject of research trials, in accordance with the legislation in force;
10. oversee the safe use of Advanced Therapeutic Products, promote awareness, and support the adoption of evidence-based practices in their use by public and private entities and Establishments;
11. cooperate and coordinate with local, federal, regional, and international entities in fields related to Longevity, in a manner that ensures the achievement of the DLA's objectives;
12. participate in local, regional, and international exhibitions, seminars, and conferences held within and outside the Emirate in fields related to Longevity;
13. propose legislation related to Longevity, including legislation concerning advanced and regenerative interventions and therapies, and submit the same to the competent entities in the Emirate to take the necessary action in respect thereof;
14. establish an integrated database for Longevity, including clinical indicators and community health and safety standards, through the exchange of data held by the Concerned Entities and the implementation of real-time data sharing, to support the generation of scientific evidence and, based on such data, the evaluation and development of policies and protocols, in compliance with the provisions of the legislation governing such data;
15. promote cooperation with universities and research institutes within and outside the Emirate in fields related to Longevity, and facilitate the exchange of research and scientific knowledge and expertise;
16. develop programmes and strategic partnerships among manufacturers of Advanced Therapeutic Products, innovators, investors, and research centres, with the aim of supporting and stimulating investment in the field of Longevity; and

17. exercise any other functions or powers required for the achievement of the objectives of the DLA as assigned to it by the Ruler or the President.

Conduct of the Activity Article (7)

- a. No natural or legal person may conduct the Activity in the Emirate, including in Special Development Zones and free zones, such as the Dubai International Financial Centre, unless that person holds a Permit issued by the DLA. The Permit will be issued in accordance with the requirements and procedures approved by the Board of Directors pursuant to a decision issued by it for this purpose.
- b. The DLA will issue the Permit, in coordination with the Concerned Entities, through the Unified Digital Window regulated under the above-mentioned Decree No. (13) of 2024, upon compliance with the requirements and procedures prescribed for its issuance, and in accordance with the classification and type of Activity related to Longevity.

Functions of the DHA and other Concerned Entities Article (8)

- a. The provisions of this Law and the resolutions issued in pursuance hereof apply without prejudice to the functions vested in the Concerned Entities under the legislation applicable to them.
- b. In exercising its functions under this Law and the resolutions issued in pursuance hereof, the DLA must do so without prejudice to the functions and powers vested in the Concerned Entities under the legislation regulating the health sector and other legislation in force in the Emirate.
- c. The DHA is hereby vested with the competence to supervise, regulate, and issue the necessary Permits to natural persons to conduct the Activity and provide services related to Longevity, in accordance with the above-mentioned Executive Council Resolution No. (49) of 2024 and in coordination with the DLA.
- d. The DLA will issue its approval to natural persons to conduct the Activity and provide services related to Longevity prior to obtaining the necessary permits from the Concerned Entities in accordance with the legislation in force in the Emirate.
- e. In the event of any overlap or conflict between the functions and powers vested in the DLA under this Law and the resolutions issued in pursuance hereof, and the powers and functions

vested in the Concerned Entities under the legislation in force, the matter will be referred to the Board of Directors to examine such overlap or conflict and submit the necessary recommendations thereon to the competent entities in the Emirate for taking the necessary measures to consider and determine the matter in accordance with the legislation in force.

Organisational Structure of the DLA

Article (9)

The organisational structure of the DLA consists of the following levels:

1. the President;
2. the Board of Directors; and
3. the executive body.

President of the DLA

Article (10)

- a. A President will be appointed to the DLA pursuant to a decree of the Ruler.
- b. The President will have the duties and powers to:
 1. approve the general policy and strategic plans related to Longevity in the Emirate;
 2. approve the initiatives, programmes, projects, studies, and recommendations that are related to Longevity, and that enable the DLA to achieve its objectives;
 3. approve the organisational structure of the DLA; and
 4. exercise any other duties or powers that are relevant to the achievement of the objectives of the DLA, as assigned to him by the Ruler.
- c. The President may delegate any of the duties and powers vested in him pursuant to paragraph (b) of this Article to the Board of Directors, provided that such delegation is specific and in writing.

Board of Directors of the DLA
Article (11)

- a. The DLA will have a Board of Directors comprised of a Chairman, a vice chairman, and a number of Members, appointed pursuant to a decree of the Ruler.
- b. The provisions of the above-mentioned Decree No. (1) of 2023 and the resolutions issued in pursuance thereof will govern the work and meetings of the Board of Directors.

Functions of the Board of Directors
Article (12)

- a. The Board of Directors will undertake general supervision of the DLA in exercising its functions and powers under this Law, the resolutions issued in pursuance hereof, and other legislation in force in the Emirate, with a view to achieving the objectives of the DLA. In particular, the Board of Directors will have the duties and powers to:
 - 1. approve the general policy and strategic plans relating to Longevity in the Emirate, and submit the same to the President for final approval;
 - 2. approve the general policy, strategic and operational plans, work programmes, and projects of the DLA;
 - 3. approve the classification of Activities, and the types, fields, practices, services, and products related to Longevity that are authorised in the Emirate, in coordination with the Concerned Entities; and issue the resolutions and regulations related thereto;
 - 4. approve the resolutions, policies, and bylaws regulating the administrative, financial, technical, and contractual work of the DLA, including the human resources regulations applicable to the DLA's employees;
 - 5. approve the draft annual budget and Financial Statements of the DLA, in preparation for final approval by the competent entities in the Emirate;
 - 6. approve the organisational structure of the DLA and submit the same to the President for final approval;
 - 7. supervise the work of the DLA and ensure the efficient and effective performance of the functions vested in it, in line with the adopted policies, strategic plans, and programmes;

8. approve the periodic reports submitted to it on the performance of the DLA, and present the same to the President for guidance;
 9. ensure the efficient management of the DLA's financial resources, and promote the integration and coordination of the roles of the DLA and the Concerned Entities; and
 10. exercise any other duties or powers required to achieve the objectives of the DLA, as may be assigned to it by the Ruler or assigned or delegated to it by the President.
- b. The Board of Directors may delegate any of its powers under paragraph (a) of this Article to any of its Members or to the Executive Director, provided that such delegation is specific and in writing.

Formation of Supporting Committees Article (13)

One or more committees will be formed by a resolution of the Chairman of the Board of Directors, comprising representatives from the Concerned Entities or other persons with relevant expertise and specialisation, to support the DLA through performing the following duties:

1. review and propose the regulations, rules, bylaws, standards, and protocols governing the conduct of the Activity and the circulation by Establishments of Advanced Therapeutic Products and other medicines related to Longevity, and coordinate with the Concerned Entities in that regard;
2. propose the categories, types, and fields of Longevity, and the related Activities authorised to be conducted in the Emirate;
3. propose the standards, requirements, and procedures governing the issuance of Permits to Establishments to conduct the Activity in the Emirate;
4. propose ethical standards governing research and trials conducted by research institutions in relation to Longevity and Advanced Therapeutic Products;
5. propose a mechanism for coordination and cooperation among Government Entities and non-government entities concerned with Longevity in studying the biological, social, and economic risks associated with the use of Advanced Therapeutic Products, and propose regulatory frameworks governing the use of such products;

6. develop general instructions and guidelines on therapeutic and preventive interventions, consumable supplies, and services related to Longevity, and general frameworks that support the adoption of healthy lifestyles that help maintain an individual's healthy lifespan;
7. propose the regulations necessary to standardise the procedures for conducting inspections and investigations, and for recording acts committed in breach of the provisions of this Law, the resolutions issued in pursuance hereof, and other legislation in force in the Emirate; and establish a mechanism for coordination among the Concerned Entities in conducting oversight and inspection operations; and
8. perform any other functions assigned to the committee(s) by the Board of Directors.

Unified Protocol Article (14)

The DLA and the DHA will, in coordination with each other, prepare and approve a Unified Protocol comprising the following:

1. requirements for the management and protection of the information and data of individuals receiving services, products, and solutions related to Longevity;
2. procedures for media briefings related to Longevity;
3. procedures for the implementation of health awareness and education programmes related to Longevity, the promotion of healthy lifestyles, and the reduction of risk factors affecting the health of individuals;
4. support for digital systems and applications related to Longevity; and
5. any other matters as determined by the Board of Directors.

Executive Body of the DLA Article (15)

The executive body of the DLA will be comprised of the Executive Director and a number of administrative, finance, and technical employees. These employees will be governed by the relevant human resources regulations approved by the Board of Directors.

Appointment and Functions of the Executive Director
Article (16)

- a. The Executive Director will be appointed by resolution of the Chairman of the Executive Council and will be subject to the provisions of the above-mentioned Law No. (8) of 2021 and the resolutions issued in pursuance thereof.
- b. The Executive Director will be directly responsible to the Board of Directors for managing the DLA and overseeing its operations and activities in a manner that ensures the achievement of its objectives and performance of its functions under this Law, the resolutions issued in pursuance hereof, and other legislation in force in the Emirate. In particular, the Executive Director will have the duties and powers to:
 - 1. develop the general policy and strategic plans related to Longevity in the Emirate, and submit the same to the Board of Directors for approval;
 - 2. prepare the general policy and the strategic and operational plans of the DLA, submit the same to the Board of Directors for approval, and follow up on their implementation upon their approval;
 - 3. prepare annual reports on the work, performance, achievements, and activities of the DLA, and on the outcomes of its approved plans, programmes, and projects; and present the same to the Board of Directors to take the appropriate action in this regard;
 - 4. prepare the organisational structure of the DLA, and submit the same to the Board of Directors for approval;
 - 5. prepare the draft annual budget and Financial Statements of the DLA, and submit the same to the Board of Directors for approval, in preparation for final approval by the competent entities in the Emirate;
 - 6. draft the resolutions governing the administrative, financial, technical, and contractual work of the DLA, including the human resources regulations applicable to the DLA's employees, and submit the same to the Board of Directors for approval;
 - 7. supervise the work of the executive body of the DLA and appoint competent and specialised employees;
 - 8. represent the DLA before third parties, and conclude the contracts and agreements required for the achievement of the objectives of the DLA, within the limits of the powers vested in him under this Law and the relevant approval authority matrix approved by the Board of Directors;

9. form permanent and temporary committees and work teams, from amongst the employees of the DLA or other persons, to assist him in performing his duties; and determine the functions, powers, and terms of reference of these committees and work teams; and
 10. exercise any other duties or powers related to the achievement of the objectives of the DLA, as assigned or delegated to him by the Board of Directors.
- c. The Executive Director may delegate any of the powers vested in him pursuant to paragraph (b) of this Article to any of the DLA's employees, provided that such delegation is specific and in writing.

Financial Resources of the DLA

Article (17)

The financial resources of the DLA will consist of:

1. the financial appropriations allocated to the DLA in the General Budget of the Government;
2. fees and charges collected by the DLA in return for its services;
3. grants and gifts received by the DLA and approved by the Board of Directors; and
4. any other resources approved by the President.

Accounts and Financial Year of the DLA

Article (18)

- a. In managing its accounts and records, the DLA will apply the rules and principles of government accounting.
- b. The Financial Year of the DLA will commence on 1 January and will end on 31 December of the same Year, except that the first Financial Year will commence on the date on which this Law comes into force and will end on 31 December of the following Year.

Administrative Violations and Penalties

Article (19)

- a. The Chairman of the Executive Council will issue a resolution determining the acts that constitute violations of this Law and the resolutions issued in pursuance hereof; and the relevant fines to be imposed on violators.

- b. In addition to the penalty of a fine, the DLA may take any of the following measures against a violator:
 - 1. suspending the Permit for a period not exceeding six (6) months;
 - 2. revoking the Permit and coordinating with the competent commercial licensing authority in the Emirate to cancel the commercial licence; or
 - 3. taking any other measures determined pursuant to a resolution of the President or by the legislation in force in the Emirate.

Suspension and Cessation of the Activity

Article (20)

The DLA may, for any reason related to serving the public interest or to regulating the Activity, services, fields, and products related to Longevity in the Emirate, take any of the following actions or measures:

- 1. suspension of Permit issuance;
- 2. suspension of an Establishment's authorised Activity in exceptional circumstances or upon the occurrence of any event that may affect operational continuity;
- 3. coordination with the DHA regarding the suspension of Permits issued to professional natural persons to practise professions related to Longevity; and
- 4. taking any other action or measure determined pursuant to the relevant resolution of the President.

Law Enforcement

Article (21)

- a. The employees of the DLA nominated pursuant to a resolution of the Executive Director will have the capacity of Law Enforcement Officers to record the acts committed in breach of the provisions of this Law and the resolutions issued in pursuance hereof. For this purpose, they may issue the necessary violation reports and, where necessary, seek the assistance of police personnel.
- b. The Executive Director may agree with the officials in charge of the Concerned Entities to grant their employees the law enforcement capacity to detect and record the acts committed in breach of the provisions of this Law and the resolutions issued in pursuance hereof. Such

law enforcement capacity will be granted in accordance with the provisions of the above-mentioned Law No. (19) of 2024 and the resolutions issued in pursuance thereof.

Grievances Article (22)

Any affected party may submit a written grievance to the Executive Director against any decision, action, or measure taken against him under this Law or the resolutions issued in pursuance hereof, within thirty (30) days from the date of being notified of the contested decision, action, or measure. The grievance will be determined, within fifteen (15) days from the date of its referral to the committee formed by the Executive Director for this purpose. The decision issued by the committee on the grievance will be final.

Cooperation with the DLA Article (23)

All local entities in the Emirate must fully cooperate with the DLA and the Concerned Entities, meet their requirements, and provide them with the data, information, documents, statistics, studies, and reports they request and deem necessary to enable the DLA to achieve its objectives and exercise its functions under this Law, the resolutions issued in pursuance hereof, and other legislation in force in the Emirate. These entities must also provide the DLA with support and assistance whenever requested to do so.

Outsourcing the DLA Functions Article (24)

The DLA may, subject to the approval of the Board of Directors and in accordance with the legislation in force, outsource any of its functions or powers under this Law and the resolutions issued in pursuance hereof to any of the Concerned Entities, or any public or private entity, pursuant to an agreement concluded with that entity for this purpose. This agreement will determine the rights and obligations of the parties and the conditions and requirements with which the contracted entity must comply when performing the functions outsourced to it by the DLA.

**Issuing Implementing Resolutions
Article (25)**

Except for the resolutions which the President is exclusively authorised to issue under this Law, the Chairman of the Board of Directors will, subject to the approval of the Board of Directors, issue the resolutions required for implementing the provisions of this Law.

**Repeals
Article (26)**

Any provision in any other legislation is hereby repealed to the extent that it conflicts with the provisions of this Law.

**Publication and Commencement
Article (27)**

This Law will be published in the Official Gazette and will come into force on the day on which it is published.

**Mohammed bin Rashid Al Maktoum
Ruler of Dubai**

Issued in Dubai on 6 June 2026
Corresponding to 20 Thu al-Hijjah 1447 A.H.